Compared to the Control group, the activated DC counts were increased to a peak on the seventh-day post-treatment in all treatment groups, with the most concentrated CD11c+ DCs around the tumor necrosis in Group C (Figure 6B). The gene discussed is ITGAX; the disease is neoplasm.